Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

Illumina's technology is extremely well-established, and serves as the backbone for most large-scale genome sequencing projects currently underway (including the majority of the samples sequenced ...

Illumina, Inc. has unveiled a service program to provide high-quality personal genome sequencing for consumers. This is the first service to offer complete coverage of the human genome sequence for ...

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s ...

For a one-time fee of $985, you can get your genome analyzed on the Web. DeCODE Genetics, based in Reykjavik, Iceland, today is launching a new service that that it says will provide a detailed ...

The first commercial whole-genome sequencing service was launched last week by startup Knome, based in Cambridge, MA. (See “Get Your Genome Sequenced for $350,000.”) ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN), an American biotechnology company, on Monday announced that it planned to acquire 23andMe Holding Co.'s Personal Genome Service, Total Health ...

Below are the statement and responses to questions KPIX 5 posed in regards to a recent special report on the accuracy of DNA testing posed to 23andMe. It is expected that identical twins receive ...

Under the proposed agreement with Regeneron, the Tarrytown, New York, drugmaker will acquire 23andMe's assets, including its personal genome service and total health and research services.

Regeneron intends to acquire 23andMe’s Personal Genome Service (PGS), Total Health, and Research Services business lines, together with its Biobank and associated assets.